TD Cowen Forecasts Strong Price Appreciation for Cencora (NYSE:COR) Stock

Cencora (NYSE:COR) had its price objective raised by TD Cowen from $350.00 to $400.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen’s price target indicates a potential upside of 10.33% from the stock’s previous close.

A number of other analysts also recently commented on the company. Wells Fargo & Company raised their price objective on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Morgan Stanley set a $330.00 target price on Cencora and gave the company an “equal weight” rating in a research note on Wednesday, July 16th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday. Finally, Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Saturday. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $355.91.

Cencora Stock Performance

NYSE:COR traded up $1.85 during midday trading on Monday, reaching $362.55. The stock had a trading volume of 464,464 shares, compared to its average volume of 1,537,779. The stock has a market capitalization of $70.29 billion, a P/E ratio of 37.28, a PEG ratio of 1.56 and a beta of 0.63. Cencora has a 1-year low of $223.92 and a 1-year high of $364.36. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The firm’s fifty day simple moving average is $314.27 and its 200-day simple moving average is $299.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same period in the prior year, the company earned $3.34 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts forecast that Cencora will post 15.37 EPS for the current fiscal year.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 41,544 shares of company stock valued at $12,230,941 in the last quarter. Corporate insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

Hedge funds and other institutional investors have recently bought and sold shares of the company. Allworth Financial LP grew its stake in shares of Cencora by 13.1% during the 1st quarter. Allworth Financial LP now owns 2,718 shares of the company’s stock worth $767,000 after acquiring an additional 315 shares in the last quarter. New York State Common Retirement Fund grew its position in Cencora by 3.7% in the first quarter. New York State Common Retirement Fund now owns 116,494 shares of the company’s stock valued at $32,396,000 after purchasing an additional 4,136 shares in the last quarter. CWM LLC increased its stake in Cencora by 0.9% in the 1st quarter. CWM LLC now owns 10,217 shares of the company’s stock valued at $2,841,000 after buying an additional 95 shares during the last quarter. Signaturefd LLC lifted its position in Cencora by 3.9% during the 1st quarter. Signaturefd LLC now owns 3,755 shares of the company’s stock worth $1,044,000 after buying an additional 141 shares in the last quarter. Finally, Apollon Wealth Management LLC boosted its stake in shares of Cencora by 11.1% during the 1st quarter. Apollon Wealth Management LLC now owns 5,949 shares of the company’s stock worth $1,654,000 after buying an additional 596 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.